Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival

Engelmann, Simon Udo and Kasparbauer, Felix and Pickl, Christoph and Del Giudice, Francesco and Haas, Maximilian and Rinderknecht, Emily and Siska, Peter J. and Pichler, Renate and Niessen, Christoph and Burger, Maximilian and Guzvic, Miodrag and Mayr, Roman (2025) Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival. JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 16 (6): e70146. ISSN 2190-5991, 2190-6009

Full text not available from this repository. (Request a copy)

Abstract

Background: Sarcopenia has emerged as a significant predictor of adverse outcomes in cancer. Specifically, this is also true for patients with bladder cancer undergoing radical cystectomy (RC). This retrospective study investigates the roles of the biomarkers interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15), in the context of sarcopenia, assessing their impact on oncological and survival outcomes. Methods: Preoperative serum IL-6 and GDF-15 levels were analysed in 179 patients undergoing RC. Their association with sarcopenia, adverse pathological features and survival outcomes was investigated. Results: Elevated IL-6 and GDF-15 levels were significantly correlated with the presence of sarcopenia (p = 0.04 and p = 0.03, respectively). IL-6 and GDF-15 levels in serum showed a positive correlation (Spearman r = 0.45, 95%CI 0.32-0.56, p < 0.01). Higher IL-6 and GDF-15 levels were also associated with higher tumour stages (both p < 0.01), positive lymph nodes (p = 0.02 and p < 0.01) and unfavourable surgical margins (both p < 0.01). Patients with both sarcopenia and high IL-6 or GDF-15 levels exhibited significantly worse overall survival and cancer-specific survival in multivariate Cox regression analysis. Conclusions: These findings highlight the interplay between IL-6, GDF-15, sarcopenia and tumour progression, suggesting that IL-6 and GDF-15 may serve as valuable prognostic biomarkers and potential therapeutic targets. Further research is warranted to explore targeted therapeutic strategies aimed at mitigating sarcopenia and systemic inflammation in this patient population.

Item Type: Article
Uncontrolled Keywords: DIFFERENTIATION FACTOR 15; PROSTATE-CANCER; WEIGHT-LOSS; INTERLEUKIN-6; GROWTH; OBESITY; GDF15; biomarkers; bladder cancer; GDF-15; interleukin 6; sarcopenia; urothelial cancer
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 20 Oct 2026 06:45
Last Modified: 20 Oct 2026 06:45
URI: https://pred.uni-regensburg.de/id/eprint/66249

Actions (login required)

View Item View Item